{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T04:24:28Z","timestamp":1758860668276},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2000,7,1]],"date-time":"2000-07-01T00:00:00Z","timestamp":962409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2000,7]]},"DOI":"10.1006\/gyno.2000.5827","type":"journal-article","created":{"date-parts":[[2002,9,17]],"date-time":"2002-09-17T22:50:18Z","timestamp":1032303018000},"page":"52-57","source":"Crossref","is-referenced-by-count":74,"title":["Paclitaxel and Cisplatin in Advanced or Recurrent Carcinoma of the Endometrium: Long-Term Results of a Phase II Multicenter Study"],"prefix":"10.1006","volume":"78","author":[{"given":"Meletios A.","family":"Dimopoulos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos A.","family":"Papadimitriou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vassilis","family":"Georgoulias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lia A.","family":"Moulopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerassimos","family":"Aravantinos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitra","family":"Gika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakelaris","family":"Karpathios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stamatios","family":"Stamatelopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1006\/gyno.2000.5827_RF1","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJM199608293350907","article-title":"Endometrial carcinoma","volume":"335","author":"Rose","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1006\/gyno.2000.5827_RF2","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1200\/JCO.1991.9.6.1071","article-title":"Systemic treatment of advanced or recurrent endometrial carcinoma: Current status and future directions","volume":"9","author":"Moore","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2000.5827_RF3","first-page":"21","article-title":"Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study","volume":"63","author":"Thigpen","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"10.1006\/gyno.2000.5827_RF4","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/0090-8258(89)90605-7","article-title":"Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study","volume":"33","author":"Thigpen","year":"1989","journal-title":"Gynecol Oncol"},{"key":"10.1006\/gyno.2000.5827_RF5","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/jnci\/80.4.276","article-title":"Phase II evaluation of carboplatin in advanced endometrial carcinoma","volume":"80","author":"Long","year":"1988","journal-title":"J Natl Cancer Inst"},{"key":"10.1006\/gyno.2000.5827_RF6","first-page":"261","article-title":"Phase III trial of doxorubicin \u00b1 cisplatin in advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study","volume":"12","author":"Thigpen","year":"1993","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1006\/gyno.2000.5827_RF7","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1200\/JCO.1994.12.7.1408","article-title":"A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study","volume":"12","author":"Thigpen","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2000.5827_RF8","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1006\/gyno.1996.0227","article-title":"A phase II trial of Taxol in advanced and recurrent adenocarcinoma of the endometrium: A Gynecologic Oncology Group study","volume":"62","author":"Ball","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1006\/gyno.2000.5827_RF9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1006\/gyno.2000.5827_RF10","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1991","journal-title":"Cancer"},{"key":"10.1006\/gyno.2000.5827_RF11","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.1990.8.12.1935","article-title":"The calculation of received dose intensity","volume":"8","author":"Hryniuk","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2000.5827_RF12","first-page":"32","article-title":"The description of chemotherapy delivery options and pitfalls","volume":"14","author":"Coppin","year":"1987","journal-title":"Semin Oncol"},{"key":"10.1006\/gyno.2000.5827_RF13","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2307\/2530297","article-title":"One-sample multiple testing procedure for Phase II clinical trials","volume":"38","author":"Fleming","year":"1982","journal-title":"Biometrics"},{"key":"10.1006\/gyno.2000.5827_RF14","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"58","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1006\/gyno.2000.5827_RF15","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0169-2607(88)90086-7","article-title":"Micro-computer-assisted univariate survival data analysis using Kaplan\u2013Meier life table estimators","volume":"27","author":"Campos-Filho","year":"1988","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1006\/gyno.2000.5827_RF16","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/00000421-199606000-00016","article-title":"Taxol is active in platinum-resistant endometrial adenocarcinoma","volume":"19","author":"Woo","year":"1996","journal-title":"Am J Clin Oncol"},{"key":"10.1006\/gyno.2000.5827_RF17","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/oxfordjournals.annonc.a010768","article-title":"Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer","volume":"7","author":"Lissoni","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1006\/gyno.2000.5827_RF18","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/BF01195344","article-title":"Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine","volume":"119","author":"Rowinsky","year":"1993","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1006\/gyno.2000.5827_RF19","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1023\/A:1008221310453","article-title":"Cisplatin, epirubicin and paclitaxel-containing chemotherapy in uterine adenocarcinoma","volume":"8","author":"Lissoni","year":"1997","journal-title":"Ann Oncol"},{"key":"10.1006\/gyno.2000.5827_RF20","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1006\/gyno.1996.0210","article-title":"Paclitaxel delivered as a 3-hour infusion with cisplatin in patients with gynecologic cancers: Unexpected incidence of neurotoxicity","volume":"62","author":"Connelly","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1006\/gyno.2000.5827_RF21","first-page":"316a","article-title":"Cisplatin\/paclitaxel vs carboplatin\/paclitaxel as first-line treatment in ovarian cancer","volume":"17","author":"DuBois","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1006\/gyno.2000.5827_RF22","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.1999.17.3.761","article-title":"Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix","volume":"17","author":"Papadimitriou","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2000.5827_RF23","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1200\/JCO.1993.11.10.2010","article-title":"Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: Neuromuscular toxicity is dose-limiting","volume":"11","author":"Rowinsky","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2000.5827_RF24","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.410350310","article-title":"Peripheral neuropathy form Taxol and cisplatin combination chemotherapy: Clinical and electrophysiological studies","volume":"35","author":"Chaudhry","year":"1994","journal-title":"Ann Neurol"},{"key":"10.1006\/gyno.2000.5827_RF25","first-page":"361a","article-title":"Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in patients with advanced gynecologic malignancies: A Gynecologic Oncology Group trial","volume":"17","author":"Fleming","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1006\/gyno.2000.5827_RF26","unstructured":"Price, F, V, Edwards, R, P, Kelley, J, L, Kunshner, A, J, Hart, L, A: A trial of outpatient paclitaxel and carboplatin for advanced, recurrent, and histologic high-risk endometrial carcinoma: Preliminary report. Sem Oncol24:78\u201382, 1997"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082580095827X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082580095827X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T07:29:29Z","timestamp":1557300569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082580095827X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,7]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2000,7]]}},"alternative-id":["S009082580095827X"],"URL":"https:\/\/doi.org\/10.1006\/gyno.2000.5827","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2000,7]]}}}